

AMENDMENTS TO THE CLAIMS

Claims 1-35. (Canceled)

36. (Currently amended) A method for the treatment of a disease condition in a mammal, which condition means the presence of specific cells that are associated with the condition by the expression of a disease specific cell surface structure, wherein one administers to the mammal a therapeutically effective amount of covalent conjugate that is able to activate T lymphocytes to lyse cells that carry the disease specific cell surface structure and comprises:

a. a biospecific affinity counterpart that is capable of binding to said surface structure, and

b. a peptide that

i. contains an amino acid sequence that is derived from staphylococcal enterotoxin A, wherein said peptide has the ability to bind to a V β of a T cell receptor, and

ii. has been mutated in that ~~one or more of the following~~ amino acid substitution residue ~~D227A~~ ~~substitutions have~~ has been made: F47A, N128A, H187A, H225A or D227A in staphylococcal enterotoxin A to show a modified ability to bind to MHC class II antigens.

37-69. (Canceled)

70. (Previously presented) A method for the treatment of a disease condition in a mammal, which condition is associated with cells having a disease specific cell surface structure comprising the step of administering a therapeutically effective amount of a covalent conjugate comprising:

a. a biospecific affinity counterpart that is capable of binding to said surface structure, and

b. a peptide that

i. contains an amino acid sequence that is derived from staphylococcal enterotoxin A, wherein said peptide has the ability to bind to a V β of a T cell receptor, and

ii. has been mutated in that the following amino acid residue has been substituted D227A in staphylococcal enterotoxin A to show a modified ability to bind to MHC class II antigens.